HC SURGICAL SPECIALISTSLIMITED (1B1) Fair Value & Analysis
Healthcare · SG · Market cap 57.5M SGD
Fair value as of: Aug 17, 2026
From 25 valuation models · updated yesterday
Share price −13.9% over the past month.
A strong business, screening 79% undervalued on our models.
What matters now
- The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (0.4300 SGD). The market is more pessimistic than our downside scenario.
- A fairly wide model range (0.4300 SGD to 1.01 SGD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
60‑month range 0.2149 SGD – 0.4439 SGD · fair‑value band 0.4300 SGD – 1.01 SGD · the 0.3400 SGD price screens below the 0.6100 SGD fair value. Dashed = 300-day average. As of Aug 17, 2026.
Analysis
HC SURGICAL SPECIALISTSLIMITED (1B1) currently trades at 0.3400 SGD, while our model-based Fair Value estimate is 0.6100 SGD, implying the stock looks roughly 79.4% undervalued today. The Quality Score stands at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, HC SURGICAL SPECIALISTSLIMITED generated revenue of 19.1M SGD at a net margin of 47.2%. Revenue declined 1.7% year over year. It earns a return on equity of 46.1%. The stock trades on a trailing P/E of 5.7. Fundamentals as of Aug 17, 2026
Our scenario range runs from 0.4300 SGD (bear case) to 1.01 SGD (bull case); at 0.3400 SGD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at 79%, 1B1 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (0.9900 SGD) versus Asset-Based (0.0900 SGD). Highest evidence: Growth DCF (80).
Notify me when 1B1 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 55
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics.
Full company description
HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics. It also offers treatment services for other conditions, such as haemorrhoids, anal fissure, hernia, anal abscess, cholecystitis, anal fistula, appendicitis, colorectal cancer, lipomas, cysts, and gastric cancer, vein laser vascular, laparoscopy, and other general and specialized medical services. In addition, the company provides orthopedic services comprising joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, wounds/lumps, tenosynovitis, tunnel syndrome, bumps, joint replacement, arthroscopic surgery, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, fractures, and orthobiologic injections. Further, it provides home care services, which include medical, nursing, physiotherapy, speech therapy, occupational therapy, and ambulance services; health screening, management of acute and chronic conditions, and pre-employment check-up; public health preparedness clinic scheme, swab and send home program, community health assist scheme, and COVID-19 swab test services. Additionally, the company offers diagnostic tests that comprise blood tests, X-Rays, ultrasound, CT scans, and MRIs. HC Surgical Specialists Limited was incorporated in 2015 and is based in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
HC SURGICAL SPECIALISTSLIMITED reported revenue of 19.1M SGD in FY2025 versus 23.4M SGD in FY2021, a compound −4.9%/yr. Reported net income was 8.4M SGD in FY2025, compounding +1.3%/yr from FY2021.
Watch 1B1: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare HC SURGICAL SPECIALISTSLIMITED with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is HC SURGICAL SPECIALISTSLIMITED (1B1) overvalued or undervalued?
What is the fair value of 1B1?
What is the quality score of 1B1?
What is the revenue of HC SURGICAL SPECIALISTSLIMITED (1B1)?
What is the net profit margin of 1B1?
Does HC SURGICAL SPECIALISTSLIMITED pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track HC SURGICAL SPECIALISTSLIMITED and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.